Exelixis Inc (EXEL) — Titan Protect Analysis

EXEL

Exelixis Inc

Healthcare · ·

$52.70

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$12.5B

Total market value of the company

Trailing P/E

16.45

Reasonably valued

Forward P/E

12.27

Based on estimated future earnings — lower means cheaper

Rev Growth

+10.0%

Year-over-year revenue change

Profit Margin

35.1%

How much profit the company keeps from each dollar of revenue

ROE

41.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$50.00

-5% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 17 analysts covering this stock

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin

https://www.exelixis.com

Country: United States Employees: 1,077 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.286

Excellent risk-adjusted returns

Kelly Fraction

0.1119

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.171

Returns exceed worst-case losses — strong risk profile

Annual Return

55.0%

Historical annualised return based on price data

Max Drawdown

-25.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.39

Very low correlation to market moves

52W High

$52.96

0% below the year high

52W Low

$33.76

56% above the year low

Avg Volume

2,667,117

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$3.02

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.76

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

96.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

41.2%

Profit from core operations before interest and tax

Free Cash Flow

$629M

Positive — the business generates more cash than it spends

Revenue (TTM)

$2.4B

Total revenue over the last 12 months

Net Income

$833M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$62.00

Target Median

$50.00

Target Low

$40.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go